Soleno Therapeutics, Inc. (NASDAQ:SLNO) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT
Company Participants
Anish Bhatnagar – Chairman, President, CEO & COO
James MacKaness – CFO & Compliance Officer
Conference Call Participants
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Presentation
Kristen Kluska
Analyst
Okay. Hi. Good afternoon, everybody. This is Kristen Kluska at Cantor. Very happy to be hosting Soleno Therapeutics. We have Dr. Anish Bhatnagar, CEO; and Jim MacKaness, CFO. Thank you both so much for being here. Really appreciate it.
Anish Bhatnagar
Chairman, President, CEO & COO
Thanks for having us, Kristen.
Question-and-Answer Session
Kristen Kluska
Cantor Fitzgerald & Co., Research Division
Absolutely. So I’ll start with the most boring question I can think of, which is just giving us a high-level overview of the company, and then we’ll get down into some of the specifics.
Anish Bhatnagar
Chairman, President, CEO & COO
Sure. So for those of us who don’t know us, Soleno Therapeutics — Kristen is adjusting her mic. We’ll give her a minute. Soleno Therapeutics is in the rare disease space. We have a recently approved drug for PWS or Prader-Willi syndrome. We have just launched in the U.S., and that is our current focus. We’re in the midst of — we have filed in Europe as well, and we’re in the midst of assessing the other opportunities for the drug.
Kristen Kluska
Cantor Fitzgerald & Co., Research Division
Okay. So up until the approval of Vykat XR, these patients had no treatment options besides addressing their growth hormone. As a result, how often were these patients checking in with their physicians? And now that this drug is available, how might that dynamic change?
Anish Bhatnagar
Chairman, President, CEO & COO
Based on claims data, we see that the younger patients who
#Soleno #Therapeutics #SLNO #Presents #Cantor #Global #Healthcare #Conference